BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 21631494)

  • 1. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine.
    Cady RK; Goldstein J; Nett R; Mitchell R; Beach ME; Browning R
    Headache; 2011; 51(7):1078-86. PubMed ID: 21631494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
    Cady RK; Schreiber CP; Beach ME; Hart CC
    Med Sci Monit; 2005 Sep; 11(9):PI65-9. PubMed ID: 16127373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
    Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
    Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
    Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL
    Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M; Hee A; Emeribe U; Silberstein S
    CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual feverfew/ginger (LipiGesic M) reanalysis of data.
    Cady R; Serrano D; Lipton R; Browning R
    Headache; 2013 Feb; 53(2):384-6. PubMed ID: 23432446
    [No Abstract]   [Full Text] [Related]  

  • 8. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials.
    Lipton RB; Stewart WF; Ryan RE; Saper J; Silberstein S; Sheftell F
    Arch Neurol; 1998 Feb; 55(2):210-7. PubMed ID: 9482363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind placebo-controlled randomized clinical trial of ginger ( Zingiber officinale Rosc.) addition in migraine acute treatment.
    Martins LB; Rodrigues AMDS; Rodrigues DF; Dos Santos LC; Teixeira AL; Ferreira AVM
    Cephalalgia; 2019 Jan; 39(1):68-76. PubMed ID: 29768938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind placebo-controlled randomized clinical trial of ginger (
    Martins LB; Rodrigues AMDS; Monteze NM; Tibaes JRB; Amaral MHA; Gomez RS; Teixeira AL; Ferreira AVM
    Cephalalgia; 2020 Jan; 40(1):88-95. PubMed ID: 31398997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
    Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
    Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.
    Diener HC; Pfaffenrath V; Schnitker J; Friede M; Henneicke-von Zepelin HH
    Cephalalgia; 2005 Nov; 25(11):1031-41. PubMed ID: 16232154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
    CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.
    Maizels M; Blumenfeld A; Burchette R
    Headache; 2004 Oct; 44(9):885-90. PubMed ID: 15447697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
    Visser WH; Winner P; Strohmaier K; Klipfel M; Peng Y; McCarroll K; Cady R; Lewis D; Nett R;
    Headache; 2004 Oct; 44(9):891-9. PubMed ID: 15447698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.